scholarly journals Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance

Oncotarget ◽  
2015 ◽  
Vol 6 (25) ◽  
pp. 20785-20800 ◽  
Author(s):  
Markus Morkel ◽  
Pamela Riemer ◽  
Hendrik Bläker ◽  
Christine Sers
2011 ◽  
Vol 49 (05) ◽  
Author(s):  
I Hritz ◽  
Z Varga ◽  
M Juhász ◽  
P Miheller ◽  
Z Tulassay ◽  
...  

2020 ◽  
Vol 22 (1) ◽  
pp. 137-145
Author(s):  
Tomasz Mackiewicz ◽  
Aleksander Sowa ◽  
Jakub Fichna

: Colitis-associated colorectal cancer (CAC) remains a critical complication of ulcerative colitis (UC) with mortality of approximately 15%, which makes early CAC diagnosis crucial. The current standard of surveillance, with repetitive colonoscopies and histological testing of biopsied mucosa samples is burdensome and expensive, and therefore less invasive methods and reliable biomarkers are needed. Significant progress has been made thanks to continuous extensive research in this field, however no clinically relevant biomarker has been established so far. This review of the current literature presents the genetic and molecular differences between CAC and sporadic colorectal cancer and covers progress made in the early detection of CAC carcinogenesis. It focuses on biomarkers under development, which can be easily tested in samples of body fluids or breath and, once made clinically available, will help to differentiate between progressors (UC patients who will develop dysplasia) from non-progressors and enable early intervention to decrease the risk of cancer development.


2012 ◽  
Vol 1 (1) ◽  
pp. 37-47
Author(s):  
Karam Singh Boparai ◽  
Yark Hazewinkel ◽  
Evelien Dekker

Author(s):  
Nazia Chaudhary ◽  
Bhagya Shree Choudhary ◽  
Sanket Girish Shah ◽  
Nileema Khapare ◽  
Nehanjali Dwivedi ◽  
...  

Cells ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 39
Author(s):  
Crescenzo Massaro ◽  
Elham Safadeh ◽  
Giulia Sgueglia ◽  
Hendrik G. Stunnenberg ◽  
Lucia Altucci ◽  
...  

Despite substantial progress in cancer therapy, colorectal cancer (CRC) is still the third leading cause of cancer death worldwide, mainly due to the acquisition of resistance and disease recurrence in patients. Growing evidence indicates that deregulation of hormone signaling pathways and their cross-talk with other signaling cascades inside CRC cells may have an impact on therapy resistance. MicroRNAs (miRNAs) are small conserved non-coding RNAs thatfunction as negative regulators in many gene expression processes. Key studies have identified miRNA alterations in cancer progression and drug resistance. In this review, we provide a comprehensive overview and assessment of miRNAs role in hormone signaling pathways in CRC drug resistance and their potential as future targets for overcoming resistance to treatment.


2015 ◽  
Vol 148 (4) ◽  
pp. S-577
Author(s):  
Johan Gagnière ◽  
Jennifer Raisch ◽  
nicolas parisot ◽  
Bruno Pereira ◽  
Virginie Bonnin ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Patricia Ahechu ◽  
Gabriel Zozaya ◽  
Pablo Martí ◽  
José Luis Hernández-Lizoáin ◽  
Jorge Baixauli ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Shinsei Yumoto ◽  
Yuji Miyamoto ◽  
Takahiko Akiyama ◽  
Yuki Kiyozumi ◽  
Kojiro Eto ◽  
...  

Abstract Background The incidence of synchronous gastrointestinal neuroendocrine tumors (GI-NETs) and colorectal cancer is very low. Case presentation We present a 72-year-old man diagnosed with a rectal neuroendocrine tumor (NET) with multiple organ metastases and simultaneous sigmoid colon cancer. Although the NET was his prognostic factor, he underwent a laparoscopic sigmoidectomy at first because it was expected that the colon cancer would cause obstruction or bleeding during NET treatment. Subsequently, he started taking everolimus. Conclusions We should consider surgical resection of the synchronous cancer before systemic therapy for a GI-NET regardless of the difference in prognosis between synchronous tumors, if the cancer may impair the continuation of systemic therapy.


2009 ◽  
Vol 15 (12) ◽  
pp. 4009-4016 ◽  
Author(s):  
Nobutake Yamamichi ◽  
Ryoichi Shimomura ◽  
Ken-ichi Inada ◽  
Kouhei Sakurai ◽  
Takeshi Haraguchi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document